Angiogenic biomarkers have been shown to improve the clinical management of preeclampsia.

Preeclampsia is a placental disease caused by trophoblast dysfunction. The angiogenic factors placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), all originating at least in part from the trophoblast, are biomarkers with predictive potential for preeclampsia and related adverse outcomes.

The 60-minute webinar focuses on how to implement biomarkers in routine preeclampsia management.